Seoul-based Lunit will collaborate with Microsoft to scale its AI-powered cancer diagnostics globally, with a strong focus on the U.S. market.
As part of the partnership, Lunit will integrate with Microsoft Azure to deliver scalable, cloud-based cancer detection tools. The two companies are codeveloping a service that allows hospitals to fine-tune AI models using their own clinical data, which could help address challenges in cross-site model performance, the company said. In addition, Lunit will build workflow automation tools using Microsoft’s agentic AI frameworks.
The collaboration follows Lunit’s acquisition last year of Volpara, and is a step for Lunit beyond standalone AI products toward integrated, enterprise-ready offerings, the company noted.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
